BaFin flags Pentixapharm 2024 financial statements, cites EUR 34.7 million intangible asset overstatement

Bitget2026/10/02 18:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bafin concluded its review of Pentixapharm’s FY2024 consolidated financial statements with an error finding.
Regulator views intangible assets as overstated by EUR 34.7 million.
Capital reserve seen overstated by EUR 21.6 million.
Overstatement includes EUR 21.6 million from purchase price allocation amounts at a former shareholder level.
Another EUR 13.1 million relates to PentixaFor development costs from 2021-2024 that Bafin says failed capitalization criteria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2409820_en) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BaFin flags Pentixapharm 2024 financial statements, cites EUR 34.7 million intangible asset overstatement

You may also like

Crypto prices